tiapridex and Substance-Withdrawal-Syndrome

tiapridex has been researched along with Substance-Withdrawal-Syndrome* in 3 studies

Reviews

2 review(s) available for tiapridex and Substance-Withdrawal-Syndrome

ArticleYear
Efficacy of tiapride in the treatment of psychiatric disorders: A systematic review.
    Human psychopharmacology, 2022, Volume: 37, Issue:5

    Tiapride is an atypical antipsychotic used to treat alcohol withdrawal, aggressiveness and agitation, headache, dyskinesias, tic and Tourette's disorder. More recently, it has been proposed for the treatment of delirium and agitation in hospitalised patients with COVID-19. Although its safety profile makes it suitable for use in vulnerable populations, the use of tiapride for psychiatric disorders is limited. This work aims to systematically review the available evidence on the efficacy and tolerability of tiapride in individuals with a psychiatric disorder.. We searched PubMed, Embase, PsycINFO, GreyLit, OpenGrey, and ProQuest up to March 2020 for randomised controlled trials focussing on the use of tiapride in the treatment of individuals with a psychiatric disorder (e.g., mood disorder, schizophrenia spectrum, substance use disorder). The Risk of Bias 2 was performed for the quality assessment of the included studies.. We identified 579 records. Of them, six studies (published between 1982 and 2010) were included in the review. Four studies referred to alcohol withdrawal, and two to the management of agitation in elderly patients with dementia. None of the studies reported significant differences between tiapride and other active comparators in terms of efficacy and tolerability. The overall risk of bias was moderate to high.. Tiapride may be considered as a relatively safe treatment option for selected patients with alcohol withdrawal or agitation in dementia. However, solid evidence of its efficacy in the scientific literature is lacking. High-quality trials remain necessary to fully sustain its use in clinical practice.

    Topics: Aged; Alcoholism; Antipsychotic Agents; COVID-19; Dementia; Humans; Substance Withdrawal Syndrome; Tiapride Hydrochloride

2022
The Efficacy of Tiapride and Carbamazepine Combination Therapy in Reducing Alcohol Withdrawal Symptoms: A Systematic Review and Meta-Analysis.
    Pharmacopsychiatry, 2019, Volume: 52, Issue:5

    Topics: Anticonvulsants; Antipsychotic Agents; Carbamazepine; Drug Therapy, Combination; Ethanol; Humans; Substance Withdrawal Syndrome; Tiapride Hydrochloride

2019

Other Studies

1 other study(ies) available for tiapridex and Substance-Withdrawal-Syndrome

ArticleYear
Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol.
    Internal and emergency medicine, 2019, Volume: 14, Issue:1

    The chronic use of alcohol can lead to the onset of an alcohol use disorder (AUD). About 50% of subjects with an AUD may develop alcohol withdrawal syndrome (AWS) when they reduce or discontinue their alcohol consumption and, in 3-5% of them, convulsions and delirium tremens (DTs), representing life-threatening complications, may occur. Unfortunately, few physicians are adequately trained in identifying and treating AWS. The Italian Society on Alcohol has, therefore, implemented a task force of specialists to draw up recommendations for the treatment of AWS with the following main results: (1) while mild AWS may not require treatment, moderate and severe AWS need to be pharmacologically treated; (2) out-patient treatment is appropriate in patients with mild or moderate AWS, while patients with severe AWS need to be treated as in-patients; (3) benzodiazepines, BDZs are the "gold standard" for the treatment of AWS and DTs; (4) alpha-2-agonists, beta-blockers, and neuroleptics may be used in association when BDZs do not completely resolve specific persisting symptoms of AWS; (5) in the case of a refractory form of DTs, the use of anaesthetic drugs (propofol and phenobarbital) in an intensive care unit is appropriate; (6) alternatively to BDZs, sodium oxybate, clomethiazole, and tiapride approved in some European Countries for the treatment of AWS may be employed for the treatment of moderate AWS; (7) anti-convulsants are not sufficient to suppress AWS, and they may be used only in association with BDZs for the treatment of refractory forms of convulsions in the course of AWS.

    Topics: Alcoholic Intoxication; Anticonvulsants; Benzodiazepines; Chlormethiazole; Humans; Phenobarbital; Propofol; Sodium Oxybate; Substance Withdrawal Syndrome; Tiapride Hydrochloride

2019